CRBU — Caribou Biosciences Share News
0.000.00%
Last trade - 00:00- $57.12m
- -$55.19m
- $11.16m
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
U.S. STOCKS ON THE MOVE-Intel, Vaxcyte, Constellation Brands
Caribou plunges as it explores sale, scraps cancer programs
Caribou falls after scrapping cell therapy programs, launches strategic review
NASDAQ RESUMED AT 04:25 PM
Brief: Caribou Biosciences To Evaluate Strategic Alternatives
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:01 PM
Caribou Biosciences Q2 net loss narrows
Caribou Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Caribou Biosciences, Inc. expected to post a loss of 32 cents a share - Earnings Preview
Caribou Biosciences Inc expected to post a loss of 32 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE -Marvell, Allbirds, Immunic
U.S. STOCKS ON THE MOVE -Shake Shack, Perpetua, Caribou Biosciences
U.S. STOCKS ON THE MOVE-Stryker, TD Synnex, Factset
Brief: Caribou Biosciences Announces The FDA Granted Regenerative Medicine Advanced Therapy (Rmat) Designation To Cb-011
Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy
Caribou Biosciences Q4 licensing revenue rises, net loss narrows
Brief: Caribou Biosciences Q4 Licensing And Collaboration Revenue USD 3.941 Million